

FORM PTO-1390 (Modified)
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

294-78

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/445174

INTERNATIONAL APPLICATION NO.
PCT/NL98/00325INTERNATIONAL FILING DATE
03 June 1998PRIORITY DATE CLAIMED
04 June 1997

TITLE OF INVENTION

A Diagnostic Test Kit for Determining a Predisposition for Breast and Ovarian Cancer, Materials and Methods for Such Determination

APPLICANT(S) FOR DO/EO/US

Egbert BAKKER, Peter DEVILEE, Anne PETRIJ-BOSCH and Garit-Jan VAN OMMEN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☐ Other items or information:

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/445174)		INTERNATIONAL APPLICATION NO. PCT/NL98/00325		ATTORNEY'S DOCKET NUMBER 294-78	
20. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO \$840.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00					
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	15 - 20 =	0	x \$18.00	\$0.00	
Independent claims	3 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/>	\$260.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,100.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).				<input type="checkbox"/> \$0.00	
SUBTOTAL =				\$1,100.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,100.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/> \$0.00	
TOTAL FEES ENCLOSED =				\$1,100.00	
				Amount to be: refunded	\$
				charged	\$

☒ A check in the amount of **\$1,100.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **08-2461** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald J. Baron
Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, New York 11791

Telephone: 516-822-3550
Facsimile: 516-822-3582


SIGNATURE

Ronald J. Baron

NAME

29,281

REGISTRATION NUMBER

03 December 1999

DATE

418 Rec'd PCT/PTO 03 DEC 1999

Title: A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination.

The present invention relates generally to the field of human genetics. In particular the invention relates to methods and means (diagnostic test kits) for studying the predisposition for certain types of cancers often having a hereditary component and more specifically to the detection of a specific type of germline mutations in genes involved or associated with certain types of hereditary cancers, in particular the (human) BRCA1 gene, which will predispose to breast and ovarian cancer. In addition, the invention reveals a molecular genetic mechanism that may have mediated the genesis of these mutations, in particular the role of Alu repetitive DNA elements present in the intronic regions of BRCA1. The invention further relates to somatic mutations of this type in the BRCA1 gene in human breast and ovarian cancer, and their use in the diagnosis and prognosis of human breast and ovarian cancer.

The invention also relates to the screening of this type of BRCA1 mutations in human genomic DNA, as part of clinical protocols for the diagnosis of inherited predisposition to breast and ovarian cancer.

Background of the invention

Breast cancer is the most common malignancy among women in the Netherlands, with a cumulative risk by age 85 of one in 11. The strongest epidemiological risk factor for the disease is a positive family history.

Depending on the age of diagnosis and occurrence of bilateral disease in the index case, first degree relatives may have a relative risk of up to 10 for developing breast cancer. In the US population, 6 to 19% of women with breast cancer have at least one affected relative at the time of diagnosis [1],

but not all of them are expected to be true genetic cases as the high incidence of breast cancer in the general population will inevitably cause some coincidental familial clustering. In an attempt to stratify the two classes, criteria to define truly inherited breast cancer have been proposed [2]. Such cases are characterized by early age of onset (premenopausal), excess of bilaterality, and clear paternal or maternal transmission with an autosomal dominant mode of inheritance. Approximately 5% of all cases comply with these criteria, while another 13% are classified as familial clustering[3]. Since early age of onset appears to be a hallmark of hereditary breast cancer, one may suspect that among these cases the genetic component is much higher. Indeed, up to 36% of cases diagnosed under the age of 30 are expected to be genetic [4]. No such data are available for the Dutch situation, and little or none of this has been confirmed at the molecular genetic level.

Linkage analysis of early-onset breast cancer families localized BRCA1 to the long arm of chromosome 17 [5]. Further analyses of additional families revealed that women inheriting a mutant allele of BRCA1 are also at increased risk for ovarian cancer [6,7]. Overall, approximately 45% of all families in which breast cancer is the predominant malignancy are due to BRCA1, as are over 80% of all families with both breast and ovarian cancer [6,8]. Female mutation carriers have been estimated to have an 87% risk to develop breast cancer before the age of 70, and 63% risk to develop ovarian cancer before that age [7]. However, significant evidence for ovarian cancer risk heterogeneity was obtained, indicating the existence of at least two classes of BRCA1 mutations; one conferring a high risk to both breast and ovarian cancer, and one conferring a high risk to breast cancer, but only a moderate risk to ovarian cancer, with the former comprising approximately 26% of all BRCA1 mutations [9]. The gene frequency of BRCA1 has been estimated to be 1 in 833 women [10]. This would imply that 1.7% of all breast.

cancer patients diagnosed between age 20 and 70 are carrier of such a mutation.

The gene structure of BRCA1 was found to consist of 22 coding exons spanning >80 kb of genomic DNA [11], and encoding a 7.8 kb transcript [12]. An unusually large exon of 3.4 kb comprises 61% of the coding domain. Over 900 mutations in BRCA1 have been published to date and compiled into an electronically accessible database [13]. Several characteristics stand out [14]. First, they are nearly ubiquitously distributed over the gene. Second, >85% of the mutations in the database lead to premature termination of protein translation. These include basepair substitutions leading to a stop codon, small insertions and deletions (of 1 to 40 basepairs) leading to a frame-shift, or splice-site mutations leading to deletions of complete exons and frame shifts. That these changes presumably inactivate gene function is supported by the finding that the great majority of breast and ovarian tumours that develop in BRCA1 mutation carriers show loss of the wildtype allele [15]. The relevance in terms of cancer predisposition of the missense mutations remains a matter of debate. Some of them appear rare polymorphic variants, as they are also observed in control samples. Others seem to affect critical residues, such as the cysteines in the amino-terminal ring finger domain [12], which are conserved in the mouse Brcal sequence [16]. Third, a number of mutations have been found repeatedly, reducing the number of distinct mutations to about 150. Two of these, the 185delAG mutation and the 5382insC mutation, each represent approximately 11% of all mutations thus far reported [14]. Reconstruction of the haplotypes bearing some of the most common mutations has provided strong evidence that they have either a single or a few common ancestors and may have been present in the population already for several centuries[17-19]. Consequently, the incidence of specific mutations is strongly dependent on the population from which the breast cancer families were ascertained. Thus the

185delAG mutation was picked up mainly in families of Ashkenazi-Jewish origin [20].

The extent of the founder-effect was highlighted by the finding that approximately 1% of all Ashkenazi Jews (i.e. regardless of a positive breast cancer family history) are carrying this mutation [21,22], 8 times that of the incidence of all mutations together in the general population [10]. Specific mutations have also been recurrently detected in breast cancer families of Swedish, British, Italian, and Austrian origin [18,23-26].

Despite the vast number of BRCA1 gene changes detected to date, there remains a discrepancy between the proportion of BRCA1 mutations predicted by linkage studies [6,8], and the actual prevalence established by mutation analysis, among breast cancer families derived from a variety of ethnic backgrounds [27-31]. In general, this is explained in two ways: either a substantial number of mutations have been missed by the applied mutation screening methodology, or the genetic heterogeneity of hereditary breast cancer is significantly greater than hitherto expected.

Relatively little information of predictive value can be gleaned from the existing data. In one set of 35 kindreds with proven BRCA1 mutations from the United Kingdom, the ovarian cancer risk heterogeneity as predicted from linkage studies could be confirmed [25]. Mutations occurring before codon 1435 conferred a significantly higher ovarian cancer risk than those occurring after this point. While this is consistent with earlier predictions based on linkage analysis [9], the current mutation distribution is at odds with the predicted lower frequency of these alleles. In addition, the expressivity of BRCA1 displays considerable inter-family variability. For example, the 185delAG mutation was detected in families with early-onset breast cancer and ovarian cancer, or late-onset breast cancer without ovarian cancer [32]. Clearly, other factors influence the expression of the

phenotype, and some of those might be genetic, others environmental. Of note, BRCA1 carriers who have a rare allele at the HRAS1 minisatellite locus were recently shown to be at a 2.8-fold increased risk for ovarian cancer relative to those carriers who had common alleles at HRAS1 [33]. However, a firm establishment of the full spectrum of BRCA1 gene changes in the population is pivotal for a more formal analysis of this matter.

An intriguing feature of BRCA1, and unexpected in the light of Knudson's two-hit inactivation theorem for tumour suppressor genes, is that somatically acquired mutations are extremely rare in ovarian tumours [34-38] and have in fact not yet been detected in 135 breast tumours [39,40]. This might indicate that inactivation of BRCA1 is not selected for during tumorigenesis of the non-inherited form of breast cancer. BRCA1 expression might be critical only during certain stages of tissue development, e.g., during puberty when the breast undergoes its final differentiation into a potential milk-producing gland [39]. However, others have argued that the mechanism of inactivation might be different from that seen in inherited cases [41]. The present invention now reveals that the unusual high concentration of Alu-elements in the BRCA1 gene intronic regions [11] favors the induction of large genomic deletions and inversions in a situation of increased genomic instability although other mechanisms leading to these mutations may also play significant roles. The present invention thus provides a diagnostic test kit (and means and methods) for determining mutations, especially deletions of relatively large stretches of nucleotides in genes associated with hereditary types of cancer, in particular such mutations (deletions of relatively large stretches of nucleotides) in the BRCA1 gene. Such mutations are difficult, if not impossible, to detect by the currently PCR-based approach (if their occurrence or the site thereof is unknown) using genomic DNA as template, which has

been most widely applied to establish the current mutation spectrum of BRCA1.

The present invention thus provides a diagnostic test kit for detecting the presence of or predisposition for e.g.

5 breast cancer, whereby a means is provided for detecting a deletion of a stretch of nucleotides from a BRCA 1 gene in a sample. Now that it is known that such mutations occur, it is within the skill of the art to arrive at means to determine the presence of these mutations, either the ones disclosed
10 herein or similar mutations. Such means may include hybridization of a probe flanking both sides of the deletion, or using two probes on either side of the deletion and amplifying the stretch in between, another way may be lack of hybridization, when using a probe hybridizing to a deleted
15 part, etc. Yet another way may be lack of amplification between one or more sets of primers targeted at or near a deleted region. This already implicates that typically multiplex PCR approaches are very suitable. Also exon-connection PCR is a very suitable approach for use in the
20 present invention. The techniques mentioned above are well known in the art and need no further explanation. Since mutations as disclosed herein may occur in one allele only, quantitative methods are often preferable. It is of course clear that the diagnostic test kit should provide all other
25 necessary means for determining the presence or absence of the mutations, such as buffers, detection means (possibly labels or markers), etc.

A convenient diagnostic test kit according to the invention apart from amplification methods such as PCR, NASBA and the
30 like is a diagnostic test kit whereby the means comprise the necessary elements for southern blotting. The deletions to be detected are typically relatively large stretches of nucleotides, particularly of a size which when subjected to PCR or similar amplification techniques would not be
35 amplified under normal reaction conditions because of their length. Typically the deletion comprises one or more exons of

the BRCA1 gene or a frameshift and/or a termination codon. An exemplified deletion that is a good marker for the predisposition for cancer is the deletion which comprises at least a major part of exon 22.

5 Another exemplified deletion that is a good marker for the predisposition for cancer is the deletion which comprises at least a major part of nucleotides 1396-1662.

Another exemplified deletion that is a good marker for the predisposition for cancer is the deletion which comprises at
10 least a major part of exons 13-16.

Another exemplified deletion that is a good marker for the predisposition for cancer is the deletion which comprises at least a major part of exon 13.

An exemplified deletion that is a good marker for the
15 predisposition for cancer is the deletion which comprises a stretch of nucleotides between two ALU-elements. This kind of deletion ties in very nicely with a suggested mechanism of the origin of these mutations and the same may also be found in other genes involved in cancer and having many of these
20 elements.

Thus the invention further provides a probe for use in a diagnostic test kit according to invention comprising a nucleic acid sequence which is a fusion of two (complementary sequences of) ALU elements, in particular of the BRCA1 gene.

25 In general the invention thus provides a probe for use in a diagnostic test kit according to the invention, which is a fusion product of two sequences adjacent to the site of a deletion of a stretch of nucleotides.

Also provided is a method for determining the presence
30 in a sample of a nucleic acid derived from a BRCA1 gene having a deletion of a stretch of nucleotides, comprising contacting said sample with at least one probe which alone or together with other means is capable of distinguishing between BRCA1 genes having said deletion and BRCA1 genes not
35 having said deletion, allowing for possible hybridization

between said probe and said nucleic acid and identifying the hybridization product.

Specific embodiments of the invention will be explained in detail below.

5

Detailed description of the invention.

The present invention in one of its embodiments, which has been described in detail in the experimental part provides a description and detection in human genomic DNA of large genomic deletions in BRCA1. In addition, the invention shows involvement of the Alu-repeat elements, present at high frequency in the intronic regions of BRCA1 [11], in generating a number of these deletions. The invention also contemplates the frequency of these deletions in the Dutch population, and their descentance from a common ancestor.

We have found that the mutation spectrum of BRCA1 as resolved up to this point [13,42] has been biased by PCR-based mutation-screening methods such as SSCP, the protein truncation test (PTT), and direct sequencing, using genomic DNA as template. We describe as examples thereof two large genomic deletions, which are not detected by these approaches, and which together comprise 38% of all BRCA1 mutations found in a sample of 170 Dutch breast cancer families [43,44]. One deletion removes 510 basepairs (bp) including exon 22 (Figure 1) and was found 8 times. The other deletion removes 3835 bp including exon 13 (Figure 2) and was found 4 times.

The haplotypes of the 8 families with the exon 22 deletion were reconstructed by typing 3 intragenic markers (D17S855, D17S1322, D17S1323) and 2 flanking markers (THRA1 and D17S1327). These haplotypes were completely concordant for the intragenic markers in at least 7 families, and the haplotype conservation extended proximally to THRA1, and distally to D17S1327, in at least 5 families, to comprise a genetic region of approximately 2 cM. The haplotypes of the 4 families with the exon 13 deletion were reconstructed in a.

similar way. These haplotypes were completely concordant for the intragenic markers in at least 2 families, and the haplotype conservation extended proximally to THRA1, and distally to D17S1327, in all 4 families, to comprise a
5 genetic region of approximately 2 cM.

Molecular characterization of the deletions revealed that the exon 22 deletion starts in intron 21 and ends within the most upstream copy of three head-to-tail arranged Alu-elements in intron 22. A 17-bp imperfect homology to the
10 intron 22 Alu-element was found at the 5' deletion breakpoint (Figure 3). The 3' breakpoint is closely flanked on either side by two 25-bp sequences strongly homologous to the Alu core-sequence implied to stimulate recombination [45].

The exon 13 deletion starts in intron 12 in an Alu-element (112 bp from the 5' end) and ends in intron 13 in a region which shares very high homology to this element (Figure 4). Both the 5' and the 3' breakpoint are closely flanked on either side by sequences strongly homologous to the 26-bp Alu core-sequence implied to stimulate
20 recombination [45].

The current invention facilitates the design of PCR-based strategies (now that the presence of this kind of mutations is known) to identify the heterozygous presence of the deletions in human genomic DNA. Oligonucleotide primers
25 can be designed so to immediately flank the deletion breakpoints, and allow the specific amplification of a deletion-junction fragment as a diagnostic endpoint. Given the size of the deletions, the wildtype BRCA1 genomic sequence would remain refractory to PCR-amplification under
30 most standard reaction conditions. PCR-based diagnosis is an essential requirement to scale up throughput in the screening for these mutations.

The current invention also pertains to the molecular mechanism which may have generated the genomic deletions in
35 the BRCA1 gene, especially since this needs to be viewed in a broader sense in that the same kind of phenomenon may be

picked up in other genes or in the same gene, but not having anything to do with the inheriting kind of cancer.

The current invention thus also pertains to the role of BRCA1 mutations in non-inherited or sporadic breast cancer.

5

Experimental part.

The exon 22 deletion was revealed by Southern blot analysis of genomic DNA digested with either HindIII or BglII. As probe we used p1424, which contains ~1-kb cDNA-derived segment from exons 14-24. A carrier of the exon 22 deletion shows aberrant bands of 9.3 kb in the HindIII digest and of 6.7 kb in the BglII digest.

The exon 13 deletion was revealed by Southern blot analysis of genomic DNA digested with either HindIII or BglII. As probes we used either p11 or p1424, which contain ~1-kb cDNA-derived segments from exon 11 and exons 14-24, respectively. A carrier of the exon 13 deletion shows an aberrant band of 6.4 kb in the HindIII pattern obtained with probe p1424 and of 14 kb in the BglII pattern obtained with probe p11.

To further characterize these deletions, we used intronic amplimers to obtain PCR-products from genomic DNA, specifically containing the deletion-junction fragment. Amplimers flanking exon 22 generated an aberrant genomic fragment of 1.4 kb in DNA samples carrying the exon 22 deletion, which turned out to contain a 510-bp deletion relative to the wildtype sequence (Figure 3). The deletion affecting exon 22 removes the bases 79505-80014 (510 bp) as listed in the genomic sequence of BRCA1 (Genbank accession nr. L78833). As a result, 74 basepairs, corresponding to exon 22, are missing in the processed mRNA-transcript (bases 79543-79616 in Genbank accession nr. L78833).

Amplimers flanking exon 13 generated an aberrant genomic fragment of 2.7 kb in DNA samples carrying the exon 13 deletion, which turned out to contain a 3835 bp deletion relative to the wildtype sequence (Figure 4). The deletion .

affecting exon 13 removes the bases 44514-48348 (3835 basepairs) as listed in the genomic sequence of BRCA1 (Genbank accession nr. L78833). As a result, 172 basepairs, corresponding to exon 13, are missing in the processed mRNA-transcript (nucleotides 46156-46327 in Genbank accession nr. L78833).

We examined 142 breast cancer families in which thusfar no BRCA1 or BRCA2 mutation had been found (refs. 43,44 and our unpublished results) for the presence of the exon 13 and exon 22 deletions. They were found in 4 and 8 families, respectively. Together with previous mutation screening results, using PTT and direct sequencing [44], these deletions thus comprise 12/32 (38%) of all families in which a BRCA1 mutation has been detected to date. Three intragenic and 2 flanking markers were used to reconstruct the disease haplotype for each of the research families carrying either the 510-bp or 3.8-kb deletion. Strong conservation of allele-lengths was observed at the intragenic loci among the haplotypes carrying the same deletion, in agreement with their descent from a common ancestor.

The haplotype in the Dutch population that carries the 510-bp deletion around exon 22 is characterized by a 155-bp allele at the microsatellite marker D17S855 in intron 20, a 122-bp allele at microsatellite marker D17S1322 in intron 19, and a 151-bp allele at microsatellite marker D17S1323 in intron 12. The haplotype in the Dutch population that carries the 3835-bp deletion around exon 13 is characterized by a 151-bp allele at D17S855, a 122-bp allele at D17S1322, and a 151-bp allele at D17S1323 in intron 12. The primer sequences used to detect these alleles are: for D17S1322: Forward (F) 5' CTAGCCTGGGCAACAAACGA 3' and Reverse (R) 5' GCAGGAAGCAGGAATGGAAC 3'; for D17S855: F 5' GGATGGCCTTT TAGAAAGTGG 3' and R 5' ACACAGACTTGTCTACTGC 3'; for D17S1323: F 5' TAGGAGATGGATTATTGGTG 3' and R 5' AAGCAACTTTGCAAT GAGTG 3'. PCR conditions have been described elsewhere [44].

Detection of the mutations

Isolation of genomic DNA and total RNA from freshly taken blood samples, and preparation of first-strand cDNA by reverse transcription, has been described [43].

cDNA analysis to detect the exon 13 deletion.

Exons 12-24 were amplified from first-strand cDNA products obtained by reverse transcription using the following primers for the first PCR: F 5'TCACAGTGCAGTGAATTGGAAG 3' and R 5' GTAGCCAGGACAGTAGAAGGACTG 3' . The obtained PCR-products were used as template for a second PCR of exons 12-24 using nested primers (F 5' GAAGAAAGAGGAACGGGCTTGG 3' and R 5' GGCCACTTTGTAAGCTCATTC 3'). PCR conditions were as described previously [43]. Five µl of the final PCR products are analysed on a 1% agarose gel.

cDNA analysis to detect the exon 22 deletion.

Exons 12-24 were amplified from first-strand cDNA products obtained by reverse transcription using the following primers for the first PCR: F 5'TCACAGTGCAGTGAATTGGAAG 3' and R 5' GTAGCCAGGACAGTAGAAGGACTG 3' . The obtained PCR-products were used as template for a second PCR of exons 20-24 using nested primers (F 5' AACCAACCAAGGTCCAAAGC 3' and R 5' GTAGCCAGGACAGTAGAAGGACTG 3'). PCR conditions were as described previously[43]. Five µl of the final PCR products are analysed on a 1% agarose gel.

Genomic PCR of the 3835-bp deletion spanning exon 13. A PCR reaction of 50 µl contains 200 ng of genomic DNA, 10 pmol primers (F 5' TAGGAGATGGATTATTGGTG 3' and R 5' TAC GTGGGTTCAACTGAAGC 3'), 0.75 Units Amplitaq Taq polymerase (Perkin-Elmer-Cetus), and 5 µl of 10x ITP/BSA buffer (500 mM KCl, 100 mM TRIS-HCl pH 8.4, 25 mM MgCl₂, 2 mg/ml BSA, 2 mM dNTPs). This mixture is heated at 94°C for 5 minutes, followed by 35 cycles of PCR (at 94°C for 45 seconds, at 52°C for 1 min. and at 72°C for

2.5 min on a Perkin-Elmer-Cetus DNA thermal Cyclor). The PCR is concluded by an incubation at 72°C for 6 minutes. Five µl of the PCR products are analysed on a 1% agarose gel.

Genomic PCR of the 510-bp deletion spanning exon 22. A
5 PCR reaction of 50 µl contains 300 ng of genomic DNA, 10 pmol
primers (F 5' TCCCATTGAGAGGTCTTGCT 3' and R 5'
ACTGTGCTACTCAAGCACCA 3'), 0.75 U Amplitaq Taq polymerase
(Perkin-Elmer-Cetus), 5 µl Optiprime buffer #6 (Stratagene)
and 0.1 mM dNTPs. Thermal cycles are as described for the
10 deletion of 3.8 kb. Five µl of the PCR products are analysed
on a 1.5% agarose gel.

Southern analysis.

Five µg of genomic DNA is digested with either
15 the restriction endonuclease BglIII or HindIII. Agarose gels
(0.8%) are run at 30V for 16 hr in TAE buffer (40 mM Tris-HAC
pH 8.3, 1 mM EDTA). Procedures for denaturing, and
transferring the separated DNA to nylon membranes (Hybond N+,
Amersham) have been described [46]. As probes we used PCR-
20 products obtained from a clone containing the complete BRCA1-
cDNA, and purified by using the QIAquick PCR Purification Kit
from QIAGEN. Probe-11 (p11) derives entirely from exon 11 and
was obtained with the primers F 5' GAAAAAAAAGTACAACCAAATGCC
and R 5' AGCCCACTTCATTAGTACTGGAAC 3', and probe-1424 (p1424)
25 contains exons 14-24 and was obtained with the primers F 5'
TACCCTATAAGCCAGAATCCAGAA 3' and R 5'
GGCCACTTTGTAAGC TCATTC 3'. Purified fragments were labelled
using the Megaprime DNA labelling System from Amersham
according to suppliers protocols. Hybridizations were carried
30 out at 65°C in 125 mM Na₂HPO₄·2H₂O, 7% SDS, 10% PEG-6000, 1
mM EDTA. Final washing was in 45 mM NaCl, 4.5 mM Na-citrate
pH 7.0, 0.1% SDS, at 65 ° C for 30 minutes.

Brief description of the drawings

Figure 1. Schematic representation of the genomic deletion spanning exon 22 of BRCA1. The intronic regions are drawn to scale relative to one another, and the exonic region are drawn to scale relative to one another, but not to intronic regions. The positions of the restriction endonucleases HindIII and BglII, used in Southern blot analysis, are indicated. The arrows indicate the presence and orientation of an Alu-element.

Figure 2. Sequence of exon 22 (upper case) and its flanking intron-sequence (lower case). The numbers refer to the genomic sequence of BRCA1 (Genbank accession nr. L78833). Starting and ending positions of the 510-bp deletion are indicated by hooked arrows and affect positions 79505-80014. The first 241 bp of an Alu-element are depicted in italics, and the boxed sequences are imperfect copies (1 and 5 mismatches, respectively) of a common 26-bp core sequence involved in recombinations leading to gene rearrangements in the LDLR gene [45]. A stretch of 17 bp at the 5' junction of the deletion is homologous to a 19-bp stretch 37 bp upstream of the 3' deletion-breakpoint (underlined with arrows).

Figure 3. Schematic representation of the genomic deletion spanning exon 13 of BRCA1. The intronic regions are drawn to scale relative to one another, and the exonic region are drawn to scale relative to one another, but not to intronic regions. The positions of the restriction endonucleases HindIII and BglII, used in Southern blot analysis, are indicated. The arrowheads indicate the presence and orientation of an Alu-element.

Figure 4. Aligned sequences of intronic regions flanking exon 13, and of the deletion-junction fragment (Jnctn). The upper sequence of each alignment corresponds to intron 12

sequences, the lower sequence intron 13 sequences. The numbers refer to the genomic sequence of BRCA1 (Genbank accession nr. L78833). The boxed sequence indicates the 10 bp where the recombination took place that led to the deletion of 3835 bp. The intron 12 sequence depicted here represents the first 180 bp of an Alu-element. The intron 12 region 44481-44551 shares an 85% identity with the intron 13 region 48316-48386. The underlined sequences are imperfect copies of a common 26-bp core sequence involved in recombinations leading to gene rearrangements in the LDLR gene [45].

References

1. Slattery ML, and Kerber RA (1993) A comprehensive evaluation of family history and breast cancer risk: the Utah Population Database. JAMA 270: 1563-1568
2. Lynch, H. T., Marcus, J. M., Watson, P., Conway, T.,
5 Fitzsimmons, M. L. & Lynch, J. F. (1989) in Genetic epidemiology of cancer (eds Lynch, H.T. & Hirayama, T.) p. 289-332, CRC Press, Inc, Boca Raton, Florida.
3. Lynch HT, Albano WA, Heieck JJ, Mulcahy GM, Lynch JF, Layton MA, and Danes BS (1984) Genetics, Biomarkers, and the
10 control of breast cancer: a review. Cancer Genet. Cytogenet. 13: 43-92
4. Claus E, Risch N, and Douglas W (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 48: 232-242
- 15 5. Hall J, Lee M, Newman B, Morrow J, Anderson L, Huey B, and King M(1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684-1689
6. Easton D, Bishop D, Ford D, Crockford G, and the Breast Cancer Linkage Consortium (1993) Genetic linkage analysis in
20 familial breast and ovarian cancer: Results from 214 families. Am. J. Hum. Genet. 52: 678-701
7. Ford D, Easton D, Bishop D, Narod S, Goldgar D, and the Breast Cancer Linkage Consortium (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692-695
- 25 8. Narod S, Ford D, Devilee P, Barkardottir R, Lynch H, Smith S, Ponder B, Weber B, Garber J, Birch J, Cornelis R, Kelsell D, Spurr N, Smyth E, Haites N, Sobol H, Bignon Y, Chang-Claude J, Hamann U, Lindblom A, Borg A, Piver M, Gallion H, Struwing J, Whittemore A, Tonin P, Goldgar D,
30 Easton D, and the Breast Cancer Linkage Consortium (1995) An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56: 254-264

9. Easton D, Ford D, Bishop D, and the Breast Cancer Linkage Consortium (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. *Am. J. Hum. Genet.* 56: 265-271
10. Ford D, Easton D, and Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. *Am. J. Hum. Genet.* 57: 1457-1462
11. Smith TM, Lee MK, Szabo CI, Jerome N, Mceuen M, Taylor M, Hood L, and King MC (1996) Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. *Genome Research* 6: 1029-1049
12. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett L, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow P, Norris F, Meera Khan P, Morrison P, Rosteck P, Lai M, Barrett J, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar R, Kamb A, Wiseman R, and Skolnick M (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266: 66-71
13. Breast Cancer Information Core (1997)
http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/
14. Couch FJ, Weber BL, Borresen AL, Brody L, Casey G, Devilee P, Fitzgerald M, Friend S, Gayther S, Goldgar D, Murphy P, Szabo C, Weber B, Wiseman R, Anderson T, Durocher F, Ganguly A, King MC, Lenoir G, Narod S, Olopade O, Plummer S, Ponder B, Serova O, Simard J, Stratton M, and Warren B (1996) Mutations and polymorphisms in the familial early onset breast cancer (BRCA1) gene. *Hum Mutat* 8: 8-18
15. Cornelis R, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BAJ, Tonin P, Hamann U, Lindblom A, Lalle P, Longy M, Olh E, Scherneck S, Bignon Y, Sobol H, Chang-Claude J, Larsson C, Spurr N, Borg A, Barkardottir RB, Narod S, Devilee

- P, and the Breast Cancer Linkage Consortium (1995) High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. *Genes Chrom. Cancer* 13: 203-210
16. Sharan S, Wims M, and Bradley A (1995) Murine Brca1: Sequence and significance for human missense mutations. *Hum. Mol. Genet.* 4: 2275-2278
17. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc J, Belanger C, Dion F, Liu Q, Skolnick M, Goldgar D, Shattuck-Eidens D, Labrie F, and Narod S (1994) Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. *Nature Genet.* 8: 392-398
18. Johannsson O, Ostermeyer EA, Hkansson S, Friedman LS, Johannsson U, Sellberg C, Brondum-Nielsen K, Sele V, Olsson H, King MC, and Borg (1996) Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. *Am. J. Hum. Genet.* 58: 441-450
19. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struwing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder BAJ, Stoppa-Lyonnet D, Easton D, King M-C, and Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. *Am. J. Hum. Genet.* 58: 271-280
20. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, Morgan K, and Narod S (1995) BRCA1 mutations in Ashkenazi Jewish women. *Am. J. Hum. Genet.* 57: 189
21. truewing J, Abeliovich D, Peretz T, Avishai N, Kaback M, Collins F, and Brody L (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. *Nature Genet.* 11: 198-200
22. oa BB, Boyd AA, Volcik K, and Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. *Nature Genet.* 14: 185-187
23. hattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L,

- Friedman L, Ostermeyer E, Szabo C, King M, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop T, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis C, Skolnick M, and Goldgar D (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: Implications for presymptomatic testing and screening. JAMA 273: 535-541
24. agner TMU, Moslinger R, Zielinski C, Scheiner O, and Breiteneder H (1996) New austrian mutation in BRCA1 gene detected in three unrelated HBOC families. Lancet 347: 1263
25. ayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, Van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton D, Stratton MR, and Ponder BAJ (1995) Germline mutations of the BRCA 1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 11: 428-433
26. aligo MA, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, Olsen R, Neuhausen S, Shattuckeids D, Conte PF, Skolnick MH, and Bevilacqua G (1996) BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene 13: 1483-1488
27. Castilla L, Couch F, Erdos M, Hoskins K, Calzone K, Garber J, Boyd J, Lubin M, Deshano M, Brody L, Collins F, and Weber B (1994) Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet. 8: 387-391
28. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, and Nagao M (1995) Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res. 55: 3521-3524
29. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, and Simard J (1996) Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. Journal Of Medical Genetics 33: 814-819

30. Xu CF, Chambers JA, Nicolai H, Brown MA, Hujeirat Y, Mohammed S, Hodgson S, Kelsell DP, Spurr NK, Bishop DT, and Solomon E (1997) Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. *Genes Chromosomes And Cancer* 18: 102-110
31. Hamann U, Brauch H, Garvin AM, Bastert G, and Scott RJ (1997) German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene. *Genes Chromosomes And Cancer* 18: 126-132
32. Friedman L, Szabo C, Ostermeyer E, Dowd P, Butler L, Park T, Lee M, Goode E, Rowell S, and King M (1995) Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. *Am. J. Hum. Genet.* 57: 1284-1297
33. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Rutledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BAJ, Cannon-Albright L, Larsson C, Goldgar DE, and Narod SA (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. *Nature Genet.* 12: 309-311
34. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, and Jeffreys A (1995) A somatic BRCA1 mutation in an ovarian tumour. *Nature Genet.* 9: 343-344
35. Merajver S, Pham T, Caduff R, Chen M, Poy E, Cooney K, Weber B, Collins F, Johnston C, and Frank T (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. *Nature Genet.* 9: 439-443
36. Takahashi H, Behbakht K, McGovern P, Chiu H, Couch F, Weber B, Friedman L, King M, Furusato M, LiVolsi V, Menzin A, Liu P, Benjamin I, Morgan M, King S, Rebane B, Cardonick A, Mikuta J, Rubin S, and Boyd J (1995) Mutation analysis of the BRCA1 gene in ovarian cancers. *Cancer Res.* 55: 2998-3002
37. Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suzumori K, and Nakamura Y (1995) Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: Four

- germline mutations, but no evidence of somatic mutation. Hum. Mol. Genet. 4: 1953-1956
38. Lancaster JM, Cochran CJ, Brownlee HA, Evans AC, Berchuck A, Futreal PA, and Wiseman RW (1996) Detection of
5 BRCA1 mutations in women with early onset ovarian cancer by use of the protein truncation test. J. Natl. Cancer Inst. 88: 552-554
39. Futreal P, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett L, Haugen-Strano A, Swensen J, Miki
10 Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soederkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart J, Marks J, Ballinger D, Barrett J, Skolnick M, Kamb A, and Wiseman R (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122
- 15 40. Katagiri T, Emi M, Ito I, Kobayashi K, Yoshimoto M, Iwase T, Kasumi F, Miki Y, Skolnick MH, and Nakamura Y (1996) Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum. Mutat. 7: 334-339
41. Thompson M, Jensen R, Obermiller P, Page D, and Holt J
20 (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9: 444-450
42. Stratton MR, and Wooster R (1996) Hereditary predisposition to breast cancer. Curr Opin Genet Dev 6: 93-97
- 25 43. Hogervorst F, Cornelis R, Bout M, Van Vliet M, Oosterwijk J, Olmer R, Bakker B, Klijn J, Vasen H, Meijers-Heijboer H, Menko F, Cornelisse C, Den Dunnen J, Devilee P, and Van Ommen G (1995) Rapid detection of BRCA1 mutations by the Protein Truncation Test. Nature Genet. 10: 208-212
- 30 44. Peelen T, Van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, Van den Ouwenland AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, Van der Luijt R, Van der Hout AH, Gille JJP, Pals G, Jedema I, Olmer R, Van Leeuwen I, Newman B, Plandsoen M, Van der Est M, Brink G, Hageman S, Arts PJW, Bakker MM,
35 Willems HW, Van der Looij E, Neyns B, Bonduelle M, Jansen R, Oosterwijk JC, Sijmons R, Smeets B, Van Asperen CJ, Meijers-

Heijboer H, Klijn JGM, De Greve J, King M-C, Menko FH, Brunner HG, Halley D, Van Ommen G-JB, Vasen HFA, Cornelisse CJ, Van 't Veer LJ, De Knijff P, Bakker E, and Devilee P (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60: 1044-1049

45. Rudiger NS, Gregersen N, and Kielland Brandt MC (1995) One short well conserved region of Alu-sequences is involved in human gene rearrangements and has homology with prokaryotic chi. Nucleic Acids Res 23: 256-260

46. Devilee P, Van den Broek M, Kuipers-Dijkshoorn N, Kolluri R, Meera Khan P, Pearson P, and Cornelisse C (1989) At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics 5: 554-560


CLAIMS

1. A diagnostic test kit for detecting the presence of or predisposition for breast cancer, whereby a means is provided for detecting a deletion of a stretch of nucleotides from a BRCA 1 gene in a sample. --
- 5 2. A diagnostic test kit according to claim 1 whereby the means comprises at least one probe for hybridization.
3. A diagnostic test kit according to claim 2 whereby the means comprise the necessary elements for Southern blotting.
- 10 4. A diagnostic test kit according to claim 2 or 3 whereby the probe comprises a sequence complementary to sequences on both sides of the deletion in the BRCA 1 gene .
5. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises one or more
- 15 exons of the BRCA1 gene.
6. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises a frameshift and/or a termination codon.
7. A diagnostic test kit according to anyone of the
- 20 foregoing claims whereby the deletion comprises at least a major part of exon 22.
8. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises a major part of nucleotides 1396-1662.
- 25 9. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises at least a major part of exons 13-16.
10. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises at least a
- 30 major part of exon 13.
11. A diagnostic test kit according to anyone of the foregoing claims whereby the deletion comprises a deletion of a stretch of nucleotides between two ALU-elements.

12. A probe for use in a diagnostic test kit according to anyone of the foregoing claims comprising a nucleic acid sequence which is a fusion of two ALU elements of the BRCA1 gene.

5 13. A probe for use in a diagnostic test kit according to anyone of claims 1-11, which is a fusion product of two sequences adjacent to the site of a deletion of a stretch of nucleotides.

14. A method for determining the presence in a sample of
10 a nucleic acid derived from a BRCA1 gene having a deletion of
a stretch of nucleotides, comprising contacting said sample
with at least one probe which alone or together with other
means is capable of distinguishing between BRCA1 genes having
said deletion and BRCA1 genes not having said deletion,
15 allowing for possible hybridization between said probe and
said nucleic acid and identifying the hybridization product.




B BgIII
 H HindIII
 ↑ Alu-repeat
 Deleted fragment
 1868 Intron-size (bp)

Figure 1

79441 agaggtcttg ctataagcct tcatccggag agtgtaggt agaggcctg ggttaagtat
 79501 gcagattact gcagtgattt Start deletion
 79561 TACAGCTGTG TGGTGCTTCT GTGGTGAAGG AGCTTTCATC ATTCAACCCTT GGCACAGtaa
 79621 gtattgggtg ccctgtcaga gagggaggac acaatatct ctctgtgag caagactggc
 79681 acctgtcagt ccctatggat gcccctactg tagcctcaga agtcttctct gccacatac
 79741 ctgtgccaaa agactccatc tgtaagggat gggtaaagat ttgagaactg cacatatata
 79801 atatactgag ggaagacttt ttccctctaa ctcttttcc catatgtccc tccccctcct
 79861 ctctgtgact gcccagcat actgtgttcc acaaatcat caagaaatga tgggctgga g
 79921 gctgggcatg gtggctcatg tctgtaatcc cagcactttg ggaggccgag gcagggtggat
 79981 cacttgtcag gagtttgaga End deletion ccagcctggc caadatgggtg aaaccccatc tgtactaaaa
 80041 aaaaaaaaaa aaaaagtagc caggcctgggt ggagcatg cc tgtaatgcc a gctatttggg
 80101 aagttgaggt gtgagcatcg cttgaacgtg ggaggcagag gttgcagtga gccaaagattg

Figure 2

004240" 42F5446Q



B BglII
H HindIII
▶ Alu-repeat
▨ Deleted fragment
5790 Intron-size (bp)

Figure 3

44423 cctgtaatcc cagcactttg ggaggccgag gcgggaggat catgtg..gt caggagatcc
 ||||| |
 48256 cctgtaaccc cagcactttg ggaggccaag gcaggcgaat cacctgaggt cgggagctcg

44481 agaccatcct ggctaacacg gtgaaacacc atttctacta aaatacaaaa aaattagcctg
|||||
Junctn agaccatcct ggctaacacg gtgaaacacc atttctacta aaatacaaaa aaattagcctg
|||||
48316 agaccagcct gaccaacatg gagaaaccac atcttctacta aaatacaaaa aaattagcctg

44541 ggcattggtgg cggggcctg taatcccagc tactcaggag gctgaagcag aagaatggct
||| |||||| | ||||| ||||| ||||| |||||
48376 ggctggttg cacatgcctg taatcccagc tacttgggag ctacgtgcc tggcctagt

Figure 4

**Declaration and Power of Attorney Patent Application
(Design or Utility)**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "A diagnostic test kit for breast and ovarian cancer, materials and methods for such determination"

the specification of which

- ☐ is attached hereto
x was filed on December 3, 1999 as application serial no. 09/445,174 and or PCT International Application number PCT/NL98/00325 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information know to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of any foreign application(s) for patent or inventor's certificate, or 35 U.S.C. §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate of PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)		
Number 97201700.8	Country EP	Day/Month/Year Filed 4 June 1997
Number	Country	Day/Month/Year Filed
Number	Country	Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

Prior Provisional Application(s)	
Serial Number	Day/Month/Year Filing Date
Serial Number	Day/Month/Year Filing Date
Serial Number	Day/Month/Year Filing Date

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or under 35 U.S.C. §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Prior U.S. or International Application(s)		
Serial Number	Day/Month/Year Filed	Status (patented, pending, abandoned)
Serial Number	Day/Month/Year Filed	Status (patented, pending, abandoned)
Serial Number	Day/Month/Year Filed	Status (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Power of Attorney

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Attorney

Registration Number

Charles R. Hoffmann	24,102
Ronald J. Baron	29,281
Gerald T. Bodner	30,449
A. Thomas Kammer	28,226
Irving N. Feit	28,601
Alan M. Sack	31,874
Algis Anilionis	36,995
Gregory W. Bachmann	41,593
Anthony E. Bennett	40,910
James F. Harrington	P-44,741
Glenn T. Henneberger	36,074
Richard LaCava	41,135
Kevin E. McDermott	35,946
Robert C. Morriss	42,910
Samir R. Patel	P-44,998
R. Glenn Schroeder	34,720
Susan A. Sipos	43,128
Roderick S.W. Turner	38,639
Steven T. Zuschlag	43,309

I hereby authorize them or others whom they may appoint to act and rely on instructions from and communicate directly with the person/organization who/which first sends this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instructed otherwise.

Please direct all correspondence in this case to at the address indicated below:

Ronald J. Baron
Hoffman & Baron, L.L.P.
6900 Jericho Turnpike
Syosset, New York 11791

Full Name of Sole or First Inventor		
Family Name <u>van Ommen</u>	First Given Name <u>Garrit-Jan</u>	Second Given Name <u>Boudewijn</u>
Residence and Citizenship		
City of Residence <u>Amsterdam</u>	State or Country of Residence <u>the Netherlands</u> <i>NLX</i>	Country of Citizenship <u>the Netherlands</u>
Post Office Address		
Street Address <u>Westerstraat 73</u>	City <u>Amsterdam</u>	State & Zip Code or Country <u>the Netherlands 1015 LW</u>
Signature of Inventor 		Date <u>14 April 2000</u>

Full Name of Second Inventor, if any		
Family Name Petrij-Bos	First Given Name Anne	Second Given Name
Residence and Citizenship		
City of Residence Leiden	State or Country of Residence the Netherlands NLX	Country of Citizenship the Netherlands
Post Office Address		
Street Address Marsweg 268	City Leiden	State & Zip Code or Country the Netherlands 2332 EW
Signature of Inventor A Bosch		Date 14 April 2000

Petrij-Bos

Anne

Second Given Name

City of Residence

Leiden

State or Country of Residence

the Netherlands *NLX*

Country of Citizenship

the Netherlands

Street Address

Marsweg 268

City

Leiden

State & Zip Code or Country	
-----------------------------	--

the Netherlands 2332 EW


Signature of Inventor

or A Bosch


Date 11/1/00

Date 14 April 2000

3-00

Full Name of Third Inventor, if any		
Family Name <u>Bakker</u>	First Given Name <u>Egbert</u>	Second Given Name
Residence and Citizenship		
City of Residence <u>Leiden</u>	State or Country of Residence the Netherlands <u>NLX</u>	Country of Citizenship the Netherlands
Post Office Address		
Street Address <u>Jan Pafflachstraat 16</u>	City <u>Leiden</u>	State & Zip Code or Country the Netherlands 2332 ZC
Signature of Inventor 		Date 14 April 2000

4-00

Full Name of Fourth Inventor, if any		
Family Name <u>Devilee</u>	First Given Name <u>Peter</u>	Second Given Name
Residence and Citizenship		
City of Residence <u>Leiden</u>	State or Country of Residence the Netherlands <u>NLX</u>	Country of Citizenship the Netherlands
Post Office Address		
Street Address <u>Zilverkarper 10</u>	City <u>Leiden</u>	State & Zip Code or Country the Netherlands 2318 NC
Signature of Inventor 		Date 14 April 2000

Full Name of Fifth Inventor, if any		
Family Name	First Given Name	Second Given Name
Residence and Citizenship		
City of Residence	State or Country of Residence	Country of Citizenship
Post Office Address		
Street Address	City	State & Zip Code or Country
Signature of Inventor		Date

Full Name of Sixth Inventor, if any		
Family Name	First Given Name	Second Given Name
Residence and Citizenship		
City of Residence	State or Country of Residence	Country of Citizenship
Post Office Address		
Street Address	City	State & Zip Code or Country
Signature of Inventor		Date